{"id":"anti-aromatase-inhibitor","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Vaginal dryness"},{"rate":"20-40%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Aromatase is an enzyme involved in the biosynthesis of estrogens from androgen precursors. Inhibiting this enzyme reduces estrogen levels, which can slow the growth of hormone receptor-positive breast cancer cells.","oneSentence":"Inhibits the enzyme aromatase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:51.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06830486","phase":"","title":"Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-02-14","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT03505736","phase":"","title":"Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-21","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT05315011","phase":"NA","title":"Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia","status":"SUSPENDED","sponsor":"University Hospital, Montpellier","startDate":"2023-05-05","conditions":"Breast Cancer, Aromatase Inhibitors","enrollment":70},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT03953157","phase":"NA","title":"Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-07","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT02095184","phase":"NA","title":"GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-05-25","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT03219476","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-02-05","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":37},{"nctId":"NCT04965688","phase":"PHASE2","title":"Biology Guided Therapy for Breast Cancer for ER Positive","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2021-08-08","conditions":"Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":2},{"nctId":"NCT05297617","phase":"PHASE2","title":"Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-10-12","conditions":"Breast Cancer","enrollment":696},{"nctId":"NCT06418347","phase":"PHASE3","title":"Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-04-01","conditions":"Polycystic Ovary Syndrome, Infertility, Female","enrollment":150},{"nctId":"NCT05306041","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2023-01-02","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT06702618","phase":"PHASE2","title":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-01","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT01897441","phase":"NA","title":"Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-06","conditions":"Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer","enrollment":31},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT06214598","phase":"NA","title":"Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors","status":"RECRUITING","sponsor":"University of Belgrade","startDate":"2024-03-01","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT06346457","phase":"","title":"Breast Cancer & Antiestrogenic Therapy & Brain","status":"NOT_YET_RECRUITING","sponsor":"International Research Training Group 2804","startDate":"2024-04-01","conditions":"Breast Cancer Female, Healthy Female, Menopause","enrollment":180},{"nctId":"NCT02648477","phase":"PHASE2","title":"Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-03-28","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":30},{"nctId":"NCT05205200","phase":"PHASE2","title":"Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-06","conditions":"Breast Cancer, Metastatic Cancer","enrollment":338},{"nctId":"NCT01298713","phase":"PHASE2","title":"Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2008-03","conditions":"Breast Neoplasms, mTor Protein","enrollment":111},{"nctId":"NCT02513329","phase":"PHASE2","title":"Stellate Ganglion Block (SGB) For Women for Breast Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-07","conditions":"Hot Flushes, Hot Flashes","enrollment":37},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT05699356","phase":"","title":"Surgical and Non Surgical Treatment Option in Poly Cystic Ovary Cases","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10-11","conditions":"Poly Cystic Ovary Treatment for Infertility","enrollment":150},{"nctId":"NCT05264649","phase":"NA","title":"Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer","status":"UNKNOWN","sponsor":"Show Chwan Memorial Hospital","startDate":"2022-05-05","conditions":"Arthralgia","enrollment":72},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT04511832","phase":"NA","title":"Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2018-03-28","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT00005970","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-05-19","conditions":"Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7","enrollment":3436},{"nctId":"NCT01446159","phase":"PHASE2","title":"Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2011-06-13","conditions":"Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer","enrollment":188},{"nctId":"NCT04161833","phase":"NA","title":"Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-11-01","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Arthralgia","enrollment":53},{"nctId":"NCT03259711","phase":"","title":"Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2001-01","conditions":"Cardiac Affections","enrollment":20000},{"nctId":"NCT01638247","phase":"PHASE3","title":"Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-08","conditions":"Male Breast Cancer","enrollment":56},{"nctId":"NCT02528383","phase":"NA","title":"Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors","status":"COMPLETED","sponsor":"Susan Tannenbaum","startDate":"2015-08","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00237198","phase":"PHASE2","title":"Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-03","conditions":"Postmenopausal Women With Advanced Breast Cancer","enrollment":47},{"nctId":"NCT02876848","phase":"NA","title":"A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-09","conditions":"Breast Neoplasms, Medication Adherence","enrollment":120},{"nctId":"NCT01896050","phase":"","title":"Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-09","conditions":"Breast Cancer, Arthralgia, Obesity","enrollment":115},{"nctId":"NCT02530411","phase":"PHASE2","title":"Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2015-04","conditions":"Neoplasms","enrollment":160},{"nctId":"NCT00365599","phase":"PHASE2","title":"Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-02","conditions":"Breast Cancer","enrollment":43},{"nctId":"NCT00119262","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-10","conditions":"Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":226},{"nctId":"NCT01814865","phase":"PHASE2","title":"Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2013-05","conditions":"Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-aromatase inhibitor","genericName":"Anti-aromatase inhibitor","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits the enzyme aromatase Used for Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}